This is an unusual time, and this year’s LEAP reflects it well: we start with Covid-19’s very sickest patients, and a Hopkins-wide team’s groundbreaking efforts to illuminate an unusual response in their immune system.
We end with a remarkable patient with a rare autoimmune disease: the legendary musician, Peter Frampton, who is not only raising awareness and research funding, but changing medical advice about how to preserve muscle function.
Corticosteroids (prednisone) are the mainstay of therapy for systemic lupus erythematosus (SLE). Prednisone works: it has anti-inflammatory and immunosuppressive actions in SLE. This is why doctors who treat lupus patients […]
Any builder will tell you that strength lies in the crosspieces, where framework or walls intersect.
This issue of LEAP celebrates intersections: between clinicians and biological scientists, between both of those groups and information scientists, between specialists of different disciplines.
Alice in Wonderland may come to mind as you read this issue of LEAP, because we are moving from the large to the small, and back again: A rheumatic disease is big, and its effect can be devastating. However, a disease such as rheumatoid arthritis, scleroderma, or Sjögren’s is, in fact, multiple diseases, each slightly different.
The first thing to remember is that everybody with a diagnosis of scleroderma is at risk of developing lung disease — either interstitial lung disease (ILD), which affects about 60 […]
For too long, doctors treating rheumatic diseases have had to base their management on instinct and experience.
The problem is that each physician has a limited experience – which means that many times we basically had to guess at how to treat a specific patient, using trial and error to find out what might work best.
